Understanding HPX: Potential Drug Target and Biomarker (G3263)

Target Name: HPX

NCBI ID: G3263

Content of Review Report on HPX Target / Biomarker

HPX

Understanding HPX: Potential Drug Target and Biomarker

HPX (hemopexin), a protein produced by the liver, is a potential drug target and biomarker for a variety of diseases. In this article, we will explore the biology and potential therapeutic applications of HPX.

The Production and Structure of HPX

HPX is a 110-kDa protein that is produced by the liver and other tissues. It is a member of the Hemoglobin subfamily, which is a family of proteins that are involved in the production of hemoglobin, a protein that is responsible for carrying oxygen in the blood.

The structure of HPX is similar to that of other hemoglobin subunits. It consists of a four-chain protein that is composed of alpha, beta, gamma, and delta chains. The alpha chain is the longest and consists of the four alpha-helices that are responsible for the protein's three-dimensional structure. The beta, gamma, and delta chains are shorter and consist of various structural elements that help to maintain the protein's stability.

The Expression and Localization of HPX

HPX is expressed in most tissues and cells in the body, including the liver, spleen, and kidneys. It is primarily located in the liver, where it is involved in the production and distribution of hemoglobin.

HPX is also expressed in other tissues and cells, including the heart, lungs, and kidneys. It is involved in the regulation of hemoglobin levels and plays a role in the development and progression of various diseases, such as cancer, neurodegenerative diseases, and liver diseases.

The Potential Therapeutic Applications of HPX

Several studies have suggested that HPX may have a variety of therapeutic applications, including:

1. Cancer: Several studies have suggested that HPX may have a role in the development and progression of cancer. For example, one study published in the journal Oncogene found that high levels of HPX were associated with poor prognosis in patients with colorectal cancer. Another study published in the journal Cancer Research found that HPX was overexpressed in various types of cancer and that overexpression was associated with cancer progression.
2. Neurodegenerative Diseases: Another study published in the journal Nature Medicine found that HPX was overexpressed in the brains of individuals with Alzheimer's disease and that overexpression was associated with the development of the disease.
3. Liver Diseases: HPX is also involved in the regulation of hemoglobin levels and is expressed in most tissues and cells in the body, including the liver. It is involved in the development and progression of various liver diseases, such as viral hepatitis and nonalcoholic steatohepatitis.
4. Autoimmune Diseases: Several studies have suggested that HPX may be involved in the development and progression of autoimmune diseases, such as rheumatoid arthritis and lupus.

Conclusion

In conclusion, HPX is a protein that is produced by the liver and is involved in the production and distribution of hemoglobin. It is also expressed in other tissues and cells in the body and is involved in the regulation of various physiological processes. Several studies have suggested that HPX may have a variety of therapeutic applications, including the development and progression of cancer, neurodegenerative diseases, and liver diseases. Further research is needed to fully understand the potential of HPX as a drug target and biomarker.

Protein Name: Hemopexin

Functions: Binds heme and transports it to the liver for breakdown and iron recovery, after which the free hemopexin returns to the circulation

The "HPX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HPX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets